Organon & Co. (NYSE:OGN) Short Interest Update

Key Points

• Short interest fell 15.9% to 18,609,663 shares as of April 15, leaving a short-interest ratio of about 1.9 days and roughly 7.3% of shares sold short.
• Earnings missed expectations: Organon reported $0.71 EPS vs. $0.83 expected and $1.46B revenue vs. $1.49B expected, with quarterly revenue down 3.5% year‑over‑year.
• Dividend and analyst view: the company announced a $0.02 quarterly dividend ($0.08 annual, ~0.6% yield), while analysts remain mixed—MarketBeat shows an average rating of "Reduce" and an average price target of $11.40.

Organon & Co. (NYSE:OGN - Get Free Report) saw a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 18,609,663 shares, a decline of 15.9% from the March 31st total of 22,133,518 shares. Based on an average daily volume of 9,901,209 shares, the short-interest ratio is presently 1.9 days. Currently, 7.3% of the company's shares are sold short.

Organon & Co. Stock Up 0.1%

OGN traded up $0.02 during trading hours on Friday, hitting $13.27. 2,398,115 shares of the company's stock were exchanged, compared to its average volume of 8,180,692. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.39. The firm has a 50 day moving average of $7.68 and a 200 day moving average of $7.76. The firm has a market cap of $3.48 billion, a P/E ratio of 18.68, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67. The company has a current ratio of 1.82, a quick ratio of 1.23 and a debt-to-equity ratio of 11.47.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.83 by ($0.12). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The business had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same period in the previous year, the company earned $1.02 earnings per share. Organon & Co.'s quarterly revenue was down 3.5% on a year-over-year basis. Analysts predict that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Monday, May 11th will be paid a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, May 11th. Organon & Co.'s dividend payout ratio is presently 11.27%.

Wall Street Analyst Weigh In

A number of brokerages have commented on OGN. BNP Paribas Exane reaffirmed a "neutral" rating and set a $14.00 target price (up from $12.00) on shares of Organon & Co. in a research note on Wednesday. Wall Street Zen downgraded shares of Organon & Co. from a "buy" rating to a "hold" rating in a research note on Saturday, January 31st. Barclays boosted their price target on shares of Organon & Co. from $7.50 to $8.00 and gave the company an "underweight" rating in a research note on Tuesday, February 24th. Piper Sandler raised shares of Organon & Co. from an "underweight" rating to a "neutral" rating and boosted their price target for the company from $5.00 to $14.00 in a research note on Tuesday. Finally, Zacks Research raised shares of Organon & Co. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 14th. Four investment analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Reduce" and an average price target of $11.40.

Institutional Investors Weigh In On Organon & Co.

Large investors have recently added to or reduced their stakes in the business. Foster Dykema Cabot & Partners LLC acquired a new position in Organon & Co. during the 3rd quarter worth approximately $29,000. Farther Finance Advisors LLC grew its holdings in Organon & Co. by 87.8% during the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company's stock worth $31,000 after acquiring an additional 2,033 shares in the last quarter. Rothschild Investment LLC grew its holdings in Organon & Co. by 73.1% during the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company's stock worth $42,000 after acquiring an additional 1,646 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in Organon & Co. during the 4th quarter worth approximately $44,000. Finally, Kestra Advisory Services LLC acquired a new position in Organon & Co. during the 4th quarter worth approximately $47,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.